---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015519"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:49:23.990331+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Atara Q2 net income $18.5M; workforce cut 20%; CCO departure; Bayer deal terminated; FDA supports tab-cel BLA path

## Summary
- Net income $18.5M ($0.18/diluted) vs net loss $83.8M in Q2 2021; includes $50.2M gain on ATOM facility sale.
- Workforce reduction of ~20% to reduce future annual cash burn by >20%; expects $6M severance charges; cash runway extended to Q1 2024.
- Bayer termination agreement: Bayer pays $4.2M, returns rights to ATA2271/ATA3271; license and collab revenue $51.6M in Q2 from termination.
- FDA recommended pathway to BLA for tab-cel without new trial; EC approval on track Q4 2022.
- Kristin Yarema, SVP & CCO, to depart effective Nov 15, 2022; severance of 12 months base salary.

## SEC filing metadata
- accession: 0000950170-22-015519
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017022015519/0000950170-22-015519-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017022015519/atra-20220802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015519
- JSON: https://secwatch.observer/filing/0000950170-22-015519.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015519.txt

## Key facts
- Executive change
  Kristin Yarema was terminated as Senior Vice President and Chief Commercial Officer at Atara Biotherapeutics, Inc..
  - Action: terminated
  - Role: Senior Vice President and Chief Commercial Officer
  source text: the employment of Kristin Yarema, the Company’s Senior Vice President and Chief Commercial Officer, will terminate effective as of November 15, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017022015519/0000950170-22-015519-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.